How well CLL (chronic lymphocytic leukemia) patients respond to the SARS-C0V-2 vaccine is the question we are all asking.
Fortunately, answers should be coming soon.
CLL Society wants you to know that Dr. Sameer Parikh of the Mayo Clinic has already begun testing Mayo’s blood cancer patients to check immune response to the SARS-CoV-2 inoculation at their clinic sites in Rochester, MN, Scottsdale and Phoenix, AZ, and Jacksonville, FL. They will soon be able to consent their blood cancer patients, including those with CLL, by phone. Once patients understand the trial and agree to enroll, Mayo will mail blood collection kits to patients’ homes to have their blood drawn locally. The samples will then be returned by mail.
At this time, this trial is open only to Mayo Clinic patients, past or present.
Here is the link to the trial for more details: Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
Contact Julianne Lunde, MA (507)266-2657 email@example.com
Additionally, Dr. Chaitra Ujjani, University of Washington, Seattle, is leading a multicenter trial with partners at CLL centers of excellence across the country to study immune response to the vaccine in CLL. The sites are:
- UW/Fred Hutch/SCCA: Amy Sperling firstname.lastname@example.org
- Dana Farber: RC – Peter Baker PeterO_Baker@DFCI.HARVARD.EDU
- UCSD: Monica Spydell email@example.com
- Ohio State: Arianna Crouse Arianna.Crouse@osumc.edu
- Huntsman: Natalie Rojas Natalie.Rojas@hci.utah.edu
- OHSU: Maria Jimenez Valencia firstname.lastname@example.org
- City of Hope: Osbaldo Rodriguez email@example.com
- MDACC: Jon Hernandez JAHernandez5@mdanderson.org
- Georgetown – Chiquita McCoy (firstname.lastname@example.org)
- University of Miami: RC – Ramon Arza email@example.com
- Cleveland Clinic: Natasha Goldsby (GOLDSBN@ccf.org)
- UC Irvine – Billy J. Sanchez firstname.lastname@example.org
That trial is now open. Call the center or doctor nearest you and ask about the “Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL.” If you have problems enrolling, email Amy Sperling at email@example.com for help.
LLS (Leukemia and Lymphoma Society) has opened its innovative COVID vaccine response trial where they will send you a lab requisition that you to take to your local LabCorp to check if you have antibodies against the COVID spike protein from the vaccine. First you must sign up for their registry where they will assemble all your medical records from all your providers. Next, after you had the blood test for the spike protein antibodies, you can access your own results on their registry when they become available. Here’s the link: https://www.ciitizen.com/LLS/.
The NIH (National Institutes of Health) are also extensively researching immune response in those with dysfunctional immunity. That would certainly include CLL patients. Visits and labs can be done in Bethesda or remotely. For more information see: COVID-19 vaccine responses to be studied in people with immune deficits.
BeTheMatch and several individual academic centers are at various stages of developing and rolling out similar trials.
We will update you as soon as we have more information on all these important trials. CLL Society is proud to play a role in helping get these answers.
Stay strong. We are all in this together.
Brian Koffman MDCM (retired) MS Ed
Co-Founder, Executive VP and Chief Medical Officer
CLL Society, Inc.